摘要
特发性肺纤维化(IPF)是一种慢性、渐进性的细胞间质病,病因和发病机制尚不明确。2种或2种以上药物联合使用可减少药物使用剂量,减轻不良反应,增加治疗靶通路,是目前IPF研究的关注热点。吡非尼酮和尼达尼布是FDA首次批准治疗IPF的多靶点治疗药物,其联合用药正处于临床试验阶段。本文对IPF的多靶点治疗进展进行综述,进一步讨论联合用药的利弊,浅谈中医在治疗IPF中的优势。
Idiopathic pulmonary fibrosis（IPF） is a chronic and progressive interstitial disease, and its etiology and pathogenesis remain unclear. The combination of two or more drugs can reduce the drug doses, reduce the side effects and enhance the therapeutic target pathway, which is currently the focus of IPF research. Pirfenidone and nintedanib are the first multi-target drugs approved by FDA for the treatment of IPF. At present, the combined use of these drugs is in clinical trials. This article reviews the progress in the treatment of IPF, reveals the advantages and disadvantages of combined drug treatment, and discuss the advantages of traditional Chinese medicine for IPF.
出处
《中南药学》
CAS
2017年第5期631-634,共4页
Central South Pharmacy
基金
国家科技重大专项"重大新药创制"子课题(No.2014ZX09509001-001)
关键词
特发性肺纤维化
多靶点治疗
吡非尼酮
尼达尼布
中药治疗
idiopathic pulmonary fibrosis
multiple targets for treatment
pirfenidone
nintedanib
traditional Chinese treatment
